Benefits Persist for Lenvatinib, Pembrolizumab in Renal Cell Cancer
Updated analysis showed longer progression-free and overall survival for patients with advanced renal cell carcinoma.
Updated analysis showed longer progression-free and overall survival for patients with advanced renal cell carcinoma.
In a study, partial vs radical cytoreductive nephrectomy for clear cell metastatic renal cell carcinoma was associated with a 54% decreased risk for other-cause mortality.
A discussion of new treatment options that have improved prognosis for patients with bladder cancer and renal cell carcinoma is the focus of a presentation at the 2023 ONA Summit.
Researchers have characterized common adverse reactions to combination lenvatinib and pembrolizumab in patients with advanced renal cell carcinoma.
A qualitative descriptive study was conducted to learn about nurses’ experiences administering care to pediatric patients with neuroblastoma who are receiving radioactive therapy.
Researchers randomly assigned patients with RCC to receive 18 mg or 14 mg of lenvatinib plus 5 mg everolimus to determine which produced better HRQOL.
Combination avelumab and axitinib has shown long-term activity in previously untreated patients with advanced renal cell carcinoma.
Increased cancer-specific mortality seen with heat-based thermal ablation versus cryoablation for tumor size 3.1 to 4 cm.
Use of cytoreductive nephrectomy with an immune checkpoint inhibitor reduced death risk by 67%.
Since FDA approval of imtainib, 40 newer tyrosine kinase inhibitor agents have been approved.